Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial

OBJECTIVE: This study assessed the efficacy and safety of LixiLan, a fixed-ratio, titratable, combination of 2 units insulin glargine (Gla-100) and 1 μg lixisenatide administered once daily via a single pen, versus Gla-100 in insulin-naïve type 2 diabetes on metformin. RESEARCH DESIGN AND METHODS: P...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Care
Autors principals: Rosenstock, Julio, Diamant, Michaela, Aroda, Vanita R., Silvestre, Louise, Souhami, Elisabeth, Zhou, Tianyue, Perfetti, Riccardo, Fonseca, Vivian
Format: Artigo
Idioma:Inglês
Publicat: American Diabetes Association 2016
Matèries:
Emerging Technologies and Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5001145/
https://ncbi.nlm.nih.gov/pubmed/27284114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc16-0046
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars